A clinical trial suggests that semaglutide, a drug used to treat obesity and diabetes, may protect cardiovascular health in a broad group of people.
But Novo Nordisk’s brief report is sparse on details and has left many doctors and scientists awaiting the trial’s full findings. Scientists involved with the trial plan to present more information later this year.
Other studies have unearthed cardiovascular clues suggesting semaglutide may do more than simply help people shed pounds. In a small trial of people with obesity and one type of heart failure, a year’s treatment with the drug. And last year, Strain and colleagues reported that Strain suspects that weight is not the only factor. In his stroke study, his team noticed that stroke risk fell relatively quickly — before study participants lost a significant amount of weight. “That was the biggest surprise to us,” he says. “You start seeing the benefit within a few months after starting the drug.” He’s expecting to see something similar with the SELECT trial.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Semaglutide used for weight loss also helps reduce heart failure symptoms, study findsSemaglutide is found in drugs including Ozempic and Wegovy.
Read more »
Virgin Galactic to launch next space tourist flight on Sept. 8We don't know the identities of the 'Galactic 03' crew yet.
Read more »
Police now say gunfire that struck two women at White Sox game may have come from inside ballparkBut three days later, they don't know for sure.
Read more »
People Are Sharing Things That Sucked When They Were Kids But Are Actually Awesome As An AdultIt's true: You really don't know everything when you're a kid.
Read more »
Wegovy reimbursement would cost Denmark up to $4 billion each year, ministry reportsThe Danish government could face an annual expenditure of up to $4 billion if it decides to reimburse Novo Nordisk's weight-loss drug, Wegovy, for nearly 900,000 individuals.
Read more »